Distribution of hookworm infections in different P/A/Ms in 2019 according to the national surveillance. by Hui-Hui Zhu (6506063)

The level of plasma catecholamine of winter-over expeditioners at different time points. by Shiying Liu (1569478)

Effect of statins in preventing a 3MC-mediated decrease in cell-cycle regulatory proteins and in DNA incorporation induced by RhoA inactivation. by Chih-Cheng Chang (540973)

The Impact of Prophylactic Dexamethasone on Nausea and Vomiting after Thyroidectomy: A Systematic Review and Meta-Analysis by Zhenhong Zou (645858)

“…Dexamethasone 8–10<b> </b>mg had a significantly greater effect for reducing the incidence of PONV than dexamethasone 1.25–5<b> </b>mg. …”

The urine metabolome differs between lean and overweight Labrador Retriever dogs during a feed-challenge by Josefin Söder (4183498)

“…Twenty-eight healthy intact male Labrador Retrievers were included, 12 of which were classified as lean (body condition score (BCS) 4–5 on a 9-point scale) and 16 as overweight (BCS 6–8). …”

A Comparative Study of Neural and Mesenchymal Stem Cell-Based Carriers for Oncolytic Adenovirus in a Model of Malignant Glioma by Atique U. Ahmed (226456)

“…Loading oncolytic adenovirus into NSCs and MSCs also led to expression of both pro- and anti-inflammatory genes and decreased vector-mediated neuroinflammation. Our results indicate that, despite possessing a comparable migratory capacity, NSCs display superior therapeutic efficacy in the context of intracranial tumors. …”

Viability of FTY720-treated T_CM A. by Rachel S. Resop (9238645)

Population-level mean antibody (Ab) responses for the protein microarray data. by John Joseph Valletta (564020)

“…<p>A: Mean antibody responses stratified by age (2-10y vs. 18-25y, top) or immune status (protected vs. susceptible, bottom) and sorted by decreasing intensity of one of the strata (old individuals, top, and protected individuals, bottom); each dot represents the mean response to an individual antigen. …”

Visualisation of significantly differentially expressed genes (DEGs). by Mohammed A. Alfattah (18271622)

“…<p>A) The number of DEGs with increased and decreased expression at each perioestrus time point, relative to expression at the oestrus time point is shown. …”

SDS-PAGE (10%) of culture supernatant of representative HESA-derived Tn5 mutants H28–35 (Table 1) cultured for 16 h. by Marion Schoof (11999106)

Histogram of gastroenteritis in a rural village, Kazakhstan, May–June 2021 (N = 154). by Madina Orysbayeva (14241331)

A T-test mean comparison of pre and post COVID-19 differences for selected variables. by Beshir Bedru Nasir (8218863)

Image_10_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.t... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_1_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_4_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_3_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_8_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_6_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_9_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_7_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”